PubMed Health⌕ Search

Biomedical subjects

B Dau

Publications and source records attributed to B Dau.

6 recordsLinked to original sources
PubMed1992

Ultrastructural localization of olfactory transduction components: the G protein subunit Golf alpha and type III adenylyl cyclase.

Electron microscopy and postembedding immunocytochemistry on rapidly frozen, freeze-substituted specimens of rat olfactory epithelia were used to study the subcellular localization of the transduction proteins Golf alpha and type III adenylyl cyclase. Antibody binding sites for both of these proteins occur in the same receptor cell compartments, the distal segments of the olfactory cilia. These segments line the boundary between organism and external environment inside the olfactory part of the nasal cavity. Therefore, they are the receptor cell regions that most likely first encounter odorous compounds. The results presented here provide direct evidence to support the conclusion that the distal segments of the cilia contain the sites of the early events of olfactory transduction.

Adenylyl Cyclases↗
PubMed1989

[Influence of self-tapping parapulpal posts on dentin structures].

A combined light and scanning electron microscopic study in human molars examined the effects of seven different parapulpal screw systems on dentin structure. Dentin changes were systematically categorized into four different groups occurring alone or in combinations. Based on these observations a less traumatic screw system must be postulated. The assessment of a modified system demonstrated a considerable reduction of dentin lesions.

Dental Pins↗
PubMed1989

[Cementable and adhesive pulpal pins as alternatives to self-threading screws].

Self-threading retentive pins are to be disputed in case of the possible dentinal damage in form of cracks and craze patterns. For a short time two new pin systems are offered on the german market. The essential retention shall be attained by cementing or otherwise by gluing in the pin channel. It is obvious that the promised elimination of cracking and crazing stands in opposition to a significantly reduced retention in the dentin, compared to self-threading systems. A general dispensation of self-threading pins is therefore not to be recommended.

Cementation↗
PubMed1987

What are the current possibilities in treating peptic ulcer disease?

There are two major principles of ulcer therapy. Today, the most widely accepted drugs are those which substantially reduce aggressive factors (i.c. acid and pepsin), namely histamine H2-receptor antagonists, antimuscarinics and antacids. Less frequently applied are mucoprotective agents like colloidal bismuth compounds and sucralfate. Prostaglandins both reduce acid secretion substantially and are believed to enhance mucosal resistance. Their anti-ulcer efficacy, however, is solely explicable by their antisecretory activity. Although mucosa-strengthening agents and H2-receptor blockers have nearly identical healing rates, mucosa-strengthening agents have inconvenient dosage regimens (four times or twice daily) and are probably less effective in relieving pain. The same holds true for antacids. Prostaglandins, antimuscarinics and antacids have dose related side effects. In contrast, H2-receptor blockers are characterized by a clear mechanism of action, convenient dosage regimens, good tolerance and a low incidence of side-effects. H2-receptor antagonists are the most effective anti-ulcer drugs presently available.

Anti-Ulcer Agents↗
PubMed1987

[H2 receptor antagonists in the therapy of peptic ulcer disease].

Today histamine-H2-receptor antagonists are the most intensively investigated drugs in the therapy of acid related diseases. They are characterized by a clear mechanism of action, a convenient application form, a high tolerability, a low incidence of side effects, and a large therapeutic window. The single nocturnal dosage regimen of H2-blockers follows the concept to reduce substantially night time acidity only, which is believed to play a decisive pathogenetic role in peptic ulcer disease, while during day time physiological acid secretion remains unaffected. The clinical efficacy of this application form has been well documented in the healing and symptomatic relief of acute peptic ulcers. However, about 30% of patients still suffer from ulcer pain after a 2 weeks treatment period. A more flexible dosage regimen, which is more adapted to the ulcer symptoms of the patient will probably lead to even better clinical results.

Anti-Ulcer Agents↗